Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04401436 · ClinicalTrials.gov registry record
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
A clinical trial of Coronavirus Disease 2019, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 240
- Enrollment target
- 3
- Study locations
NCT04401436 is a study of Coronavirus Disease 2019 that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 240 participants, below the 413-participant average among 4 other Coronavirus Disease 2019 trials with a reported enrollment target (42% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04401436, a study of Coronavirus Disease 2019, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 240 participants
- Enrollment target
- 3
- Study locations
Study Summary
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. Researchers want to better understand how SARS-CoV-2 affects these blood cells. This information may give them ideas for new treatments. Objective: To learn more about how SARS-CoV-2 affects lymphocytes, the immune, and the blood clotting system. Eligibility: Adults age 18 and older who either currently have COVID-19 or have recently recovered from it Design: Participants will give a blood sample. For this, a needle is used to collect blood from an arm vein. For participants who have a central line, blood will be collected through that instead. Participants medical records related to COVID-19 will be reviewed. Participants who have recovered from COVID-19 will be asked to undergo leukapheresis to collect white blood cells. For this, blood is taken from a needle placed in one arm. A machine separates out the white blood cells. The rest of the blood is returned to the participant through a needle placed in the other arm. This takes about 2-3 hours. Recovered participants may have material collected from inside the nostrils and/or rectum. This is done by gently rubbing the area with a sterile cotton swab. Recovered participants may have an echocardiogram to look at their heart. For this, a small probe is held against the chest to get pictures of the heart from different angles. This takes less than 30 minutes. Participation lasts 1-2 days on most cases and may be split in a few visits for recovered patients if leukapheresis and echocardiogram are done. ...
Conditions Studied
Study Locations (3)
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
- MedStar Health Research Institute: Washington Hospital Medical Center - Washington D.C.
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2025-02-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04401436
The ClinicalTrials.gov registry entry for NCT04401436 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 413-participant average among 4 other Coronavirus Disease 2019 trials with a reported enrollment target (42% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronavirus Disease 2019 appearing as the primary indexed condition, and to 0 interventions.
NCT04401436 reports 3 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT04401436 about?
NCT04401436 is a clinical study titled "COVID-19 Associated Lymphopenia Pathogenesis Study in Blood". Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2,...
What is the current status of trial NCT04401436?
This trial is currently completed. The enrollment target is 240 participants. The study started on 2020-05-22. Estimated completion is 2025-02-24.
What conditions does trial NCT04401436 study?
This clinical trial studies the following conditions: Coronavirus Disease 2019.
Who is sponsoring clinical trial NCT04401436?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04401436 being conducted?
This trial has 3 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronavirus Disease 2019
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
ACTIVE NOT RECRUITING
-
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
COMPLETED · Phase 2
-
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.